Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About David E. Lazar

David E. Lazar is recorded as CEO and Chairman at Indaptus Therapeutics, Inc. (INDP) and CEO and Board Member at Stablecoin Development Corp (SDEV). Indaptus Therapeutics, Inc. reported in an 8-K filed June 5, 2026 that David E. Lazar resigned as Director, effective June 5, 2026. Indaptus Therapeutics, Inc. reported in an 8-K filed March 24, 2026 that David E. Lazar resigned as co-Chief Executive Officer, effective March 18, 2026. Indaptus Therapeutics, Inc. reported in an 8-K filed December 23, 2025 that David E. Lazar was appointed Co-Chief Executive Officer, effective December 23, 2025. Equibles holds 7 filed executive changes naming David E. Lazar; each is listed under recent activity with its source filing.

“Effective as of June 5, 2026, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi resigned from all directorship positions, including from all committees served, on the Board of Directors (the "Board") of Indaptus Therapeutics, Inc. (the "Company").”
Indaptus Therapeutics, Inc. Form 8-K, filed June 5, 2026 · Read the filing
“David Lazar resigned as co-Chief Executive Officer on March 18, 2026, but remains on the Board of Directors, while stepping down as Chairman.”
Indaptus Therapeutics, Inc. Form 8-K, filed March 24, 2026 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Indaptus Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Leadership on record at Stablecoin Development Corp

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.